Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.59 AUD | -1.20% | +3.45% | +54.66% |
05-21 | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
05-20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.66% | 3.5B | |
+64.17% | 62.59B | |
-1.92% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.52% | 26.21B | |
-21.93% | 19.09B | |
+3.89% | 13.08B | |
+25.37% | 12.26B | |
+27.94% | 12.05B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Appoints Chief Commercial Officer